(-0.14%) 5 205.50 points
(-0.11%) 39 153 points
(-0.17%) 18 155 points
(0.61%) $79.47
(-0.23%) $2.18
(-0.07%) $2 320.60
(1.12%) $27.91
(0.62%) $990.70
(0.11%) $0.931
(0.15%) $10.91
(0.11%) $0.801
(0.45%) $92.16
Live Chart Being Loaded With Signals
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...
Stats | |
---|---|
今日成交量 | 343 447 |
平均成交量 | 2.33M |
市值 | 866.20M |
EPS | $0 ( 2024-03-25 ) |
下一个收益日期 | ( $-0.320 ) 2024-05-23 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.91 |
ATR14 | $0.0140 (0.19%) |
音量 相关性
Mesoblast Limited 相关性 - 货币/商品
Mesoblast Limited 财务报表
Annual | 2023 |
营收: | $7.50M |
毛利润: | $-20.23M (-269.72 %) |
EPS: | $-1.050 |
FY | 2023 |
营收: | $7.50M |
毛利润: | $-20.23M (-269.72 %) |
EPS: | $-1.050 |
FY | 2022 |
营收: | $10.21M |
毛利润: | $-20.55M (-201.21 %) |
EPS: | $-1.330 |
FY | 2021 |
营收: | $7.46M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.817 |
Financial Reports:
No articles found.
Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。